STAT6 Protein
Product Introduction
STAT6 (Signal Transducer and Activator of Transcription 6) is an important member of the STAT family (including STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6) and plays an irreplaceable regulatory role in the type II immune response of the body. The most notable feature of this protein is its specific responsiveness to IL-4 and IL-13 signals—STAT6 is the only protein in the STAT family that specifically responds to IL-4 and IL-13 signals, with irreplaceable function. STAT6 is activated through the classical JAK-STAT signaling pathway: when extracellular IL-4 or IL-13 bind to cell surface receptors, JAK kinases phosphorylate the receptor cytoplasmic tails, providing docking sites for STAT6. After recruitment, STAT6 itself is phosphorylated at tyrosine residue Y641 by JAK, then forms homodimers via its SH2 domain, translocates into the nucleus, and regulates the transcriptional expression of target genes. STAT6 primarily regulates the expression of Th2 immune response-related genes such as Arg-1, Mrc-1, Fizz-1, and Ym-1.
Product Specifications
Parameter | Specification |
Source | Recombinant expression in E. coli |
Molecular Weight | ~94 kDa |
Concentration | 1 mg/ml |
Purity | ≥95% (SDS-PAGE) |
Endotoxin | <1 EU/μg |
Storage Buffer | 50 mM Tris-HCl, 500 mM NaCl, 50% Glycerol, pH 8.0 |
10× Reaction Buffer | 200 mM Tris-HCl, 1 M NaCl, 1 mM EDTA, pH 7.5 |
Storage Conditions | Long-term storage at -80°C; short-term storage at -20°C |
Product Sizes
Specifications | Catalog Number | Concentration | Volume |
50 μL | GR300501 | 1 mg/mL | 50 μL |
250 μL | GR300502 | 1 mg/mL | 250 μL |
500 μL | GR300503 | 1 mg/mL | 500 μL |
Application Scenarios
Immunology Research:
STAT6 is a key transcription factor for Th2 cell differentiation and plays a central role in the pathogenesis of allergic diseases such as asthma and atopic dermatitis.
It induces macrophage polarization toward the M2 repair phenotype, participating in tissue damage repair and immune tolerance regulation.
It assists B cells in producing IgE antibodies, mediating humoral immune responses.
Reference
He, K., Barsoumian, et al. (2023). Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer. Cancer Immunology Research, 11(4), 486–500.